Recombinant Human GLA Protein(His Tag)

SKU: PDMH100451

Size:100μg

Storage:Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80℃. Reconstituted protein solution can be stored at 4-8℃ for 2-7 days. Aliquots of reconstituted samples are stable at < -20℃ for 3 months.

Shipping:This product is provided as lyophilized powder which is shipped with ice packs.

Exp date:12 months

Category ID_II:Recombinant Proteins

Category ID_III:Others

Abbreviation:GLA

Target Synonym:GLA;GALA;Alpha-D-Galactoside;Galactohydrolase;galactosidase alpha;GLAL;Melibiase;Agalsidase;Alpha-galactosidase A;Alpha-D-galactosidase A;Alpha-D-galactoside galactohydrolase;Galactosylgalactosylglucosylceramidase GLA

Research Areas:Metabolism;Cell Biology

Conjugation:

Target Species:Human

Expression Host:Mammalian

Application:

Fusion tag:C-His

UNIProt ID:P06280

Accession:P06280

Background:Alpha-galactosidase A, also known as Alpha-D-galactoside galactohydrolase, Alpha-D-galactosidase A, Melibiase and GLA, is a member of the glycosyl hydrolase 27 family. GLA is used as a long-term enzyme replacement therapy in patients with a confirmed diagnosis of Fabry disease. Defects in GLA are the cause of Fabry disease (FD) which is a rare X-linked sphingolipidosis disease where glycolipid accumulates in many tissues. The disease consists of an inborn error of glycosphingolipid catabolism. FD patients show systemic accumulation of globotriaoslyceramide (Gb3) and related glycosphingolipids in the plasma and cellular lysosomes throughout the body. Clinical recognition in males results from characteristic skin lesions (angiokeratomas) over the lower trunk. Patients may show ocular deposits, febrile episodes, and burning pain in the extremities. Death results from renal failure, cardiac or cerebral complications of hypertension or other vascular disease. Deficiency of GLA leads to the accumulation of glycosphingolipids in the vasculature leading to multiorgan pathology. In addition to well-described microvascular disease, deficiency of GLA is also characterized by premature macrovascular events such as stroke and possibly myocardial infarction.

Concentration:

Activity:Not validated for activity

Sequence:Met1-Leu429

Purity:> 95% as determined by reducing SDS-PAGE.

Formulation:Lyophilized from a 0.2 μm filtered solution in PBS with 5% Trehalose and 5% Mannitol.

Reconstitution:It is recommended that sterile water be added to the vial to prepare a stock solution of 0.5 mg/mL. Concentration is measured by UV-Vis

Endotoxin:< 1.0 EU/mg of the protein as determined by the LAL method

Calculated MW:47.2 kDa

ObservedMW:42-60 kDa